search
Back to results

Effect of Protein Intake on Post Prandial Hyperglycemia in Children and Adolescents With Type1 Diabetes Mellitus

Primary Purpose

Diabetes Mellitus, Type 1, Hyperglycemia, Postprandial

Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Whey protein isolate
Sponsored by
University Hospitals Cleveland Medical Center
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional diagnostic trial for Diabetes Mellitus, Type 1

Eligibility Criteria

5 Years - 17 Years (Child)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

. Duration of type 1 diabetes for > 1year.

  • On insulin pump or multiple daily injection regimen
  • Uses a personal Dexcom CGM
  • Age: 5- 17 years
  • HbA1C range: < 9%

Exclusion Criteria:

  • Hyperlipidemia
  • Diabetic gastroparesis
  • Dietary restrictions
  • Celiac disease and other malabsorption syndromes
  • Uncontrolled hypothyroidism
  • Chronic use of steroids or antipsychotics
  • Metabolic disorders of gluconeogenesis
  • Use of oral hypoglycemic agents
  • Participating in another clinical trial

Sites / Locations

  • University Hospitals Cleveland medical Center

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm 5

Arm 6

Arm Type

Active Comparator

Experimental

Experimental

Experimental

Experimental

Experimental

Arm Label

Protein consumption : 0 gm

Protein consumption : 12.5 gm

Protein consumption : 25 gm

Protein consumption :37.5 gm

Protein consumption : 50 gm

Protein consumption : 62.5 gm

Arm Description

Participant's glucose levels are monitored from hour 0 to hour 5 after consumption of 0 gm of whey protein isolate

Participant's glucose levels are monitored from hour 0 to hour 5 after consumption of 12.5 gm of whey protein isolate

Participant's glucose levels are monitored from hour 0 to hour 5 after consumption of 25 gm of whey protein isolate

Participant's glucose levels are monitored from hour 0 to hour 5 after consumption of 37.5 gm of whey protein isolate

Participant's glucose levels are monitored from hour 0 to hour 5 after consumption of 50 gm of whey protein isolate

Participant's glucose levels are monitored from hour 0 to hour 5 after consumption of 62.5 gm of whey protein isolate

Outcomes

Primary Outcome Measures

Number of positive events for each protein amount.
Events of postprandial hyperglycemia were defined as rise in glucose >50 mg/dL compared to baseline

Secondary Outcome Measures

Full Information

First Posted
November 22, 2020
Last Updated
December 3, 2020
Sponsor
University Hospitals Cleveland Medical Center
search

1. Study Identification

Unique Protocol Identification Number
NCT04655131
Brief Title
Effect of Protein Intake on Post Prandial Hyperglycemia in Children and Adolescents With Type1 Diabetes Mellitus
Official Title
Effect of Protein Intake on Post Prandial Hyperglycemia in Children and Adolescents With Type1 Diabetes Mellitus
Study Type
Interventional

2. Study Status

Record Verification Date
December 2020
Overall Recruitment Status
Completed
Study Start Date
June 18, 2018 (Actual)
Primary Completion Date
November 25, 2018 (Actual)
Study Completion Date
November 25, 2018 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University Hospitals Cleveland Medical Center

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
In type 1 Diabetes Mellitus, patients receive insulin doses if they consume specific amounts of carbohydrates. Currently, insulin is not being administered for consumption of protein although studies in adults show that consuming about 75 grams of protein causes elevation in post prandial glucose levels and might need insulin coverage. We are proposing that this amount is different for kids and it might vary based on weight, age, pubertal stage, HbA1C or other factors. This has not been studied in children before, and it will provide information about the amount of protein in the diet that can cause elevation in post prandial glucose.
Detailed Description
In target glycemic control in children with type 1 diabetes (T1D) continues to be a challenge despite advances in methods of insulin delivery and medical knowledge in this area. One of the major aspects is controlling postprandial glycemia (PPG). The relationship between dietary intake of carbohydrates and PPG is well established, and the use of insulin coverage for carbohydrate intake is standard of care. Insulin dose for carbohydrate coverage increases with body weight and progression through puberty. Multiple researchers have attempted to study the effect of dietary intake of protein and fat on PPG as well, but this relationship is not well established in the pediatric age group and there are not clear guidelines for patients on when and how to give insulin for protein intake. Meals with high protein content have been shown to cause higher glucose excursions in patients with T1D, and lower glycemic response in healthy individuals which suggests that physiologic response to protein intake involves higher insulin secretion. This has also been demonstrated by Sun et al, where they showed an increase in insulinemic index in healthy individuals when consuming chicken with rice compared to rice alone. The effect of dietary protein in individuals with T1D has been studied in mixed meals several times. Smart et al demonstrated that the greatest glucose excursions after high protein low fat meal occurred most significantly form min 150 to 300 after the meal, when insulin is given to cover carbohydrates only. In 2013, Borie-Swinburne et al measured interstitial glucose levels by CGM in 28 c-peptide negative T1D patients, on two consecutive nights, with and without addition of 21.5 grams of protein to dinner (40 g vs 61.5 g). They concluded that no additional insulin is needed to cover for the added protein. Neu et al studied 15 adolescents with T1D on two consecutive nights. They used CGM monitoring for 12 hours, and they compared the area under the curve (AUC) between regular meals and fat/ protein rich meal. They found a significant difference and they recommended additional insulin for fat /protein rich meals. Investigating the effect of protein-only intake is also an area of research focus. Paterson et al studied 27 patients with TID , aged 7-40 yrs, where they were given 6 test meals of varying amounts (0g, 12.5g, 25g, 50g, 75g and 100g) of pure protein without giving insulin. Postprandial glycemia was found to be significantly higher only for 75 and 100 grams of protein compared to the lower quantities. Glucose levels were slower to rise when compared to consumption of 20 grams of carbohydrates. Paterson et al also conducted another study with slightly different design: 27 participants with T1D [aged 10-40 years, HbA1c ≤ 64 mmol/mol (8%), BMI ≤ 91st percentile] received a 30-g carbohydrate (negligible fat) test drink with a variable amount of protein daily over 5 days in randomized order. Protein (whey isolate 0 g/kg carbohydrate, 0 g/kg lipid) was added in amounts of 0 (control), 12.5, 25, 50 and 75 g. A standardized dose of insulin was given for the carbohydrate. PPG was assessed by 5 hours of continuous glucose monitoring. Increasing protein quantity in a low-fat meal containing consistent amounts of carbohydrate decreases glucose excursions in the early (0-60-min) postprandial period and then increases in the later postprandial period in a dose-dependent manner. In summary, Paterson et al concluded that there was a threshold for dietary protein intake (75 grams), and only protein intake above this threshold regardless of body weight would result in post prandial hyperglycemia. However, these studies included a wide range of ages and did not adjust for body weight in their analysis. B. Innovation The purpose of this study is to explore the role of weight in the relationship between protein intake and post prandial glucose (PPG) levels. The study design (36 children each receiving 6 increasing nominal doses of protein) allows for the relationship to be studied both across patients of varying weights within each nominal dose, and across patients (whose weights remain the same) across the increasing doses. Our aims: Aim 1: To describe the relationship of weight (in kg), and mg of protein per kg body weight, to PPG, graphically and statistically, at each nominal dose. The heaviest children will receive the lowest mg/kg amount of protein at each nominal dose, so these relationships with PPG will be inverse. Additionally, children with different weights and receiving different nominal doses, may be receiving the same mg/kg protein. Observing all nominal doses together will allow us to determine whether the relationship, if any, is linear, demonstrates a threshold, or exhibits a doseresponse curve, as examples. Aim 2: To describe graphically and statistically the relationship of dose of protein to PPG by patient across increasing doses. Since the weight remains constant (or approximately constant) within a patient, adjustment by weight would yield the same results. The expectation is that these results will confirm those from Aim 1. Aim 3: To construct a multivariate mixed model where any observed relationships can be controlled for other demographic and clinical characteristics possibly associated with blood glucose levels. The type of model will depend on the results of Aims 1 and 2.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Diabetes Mellitus, Type 1, Hyperglycemia, Postprandial

7. Study Design

Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Sequential Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
11 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Protein consumption : 0 gm
Arm Type
Active Comparator
Arm Description
Participant's glucose levels are monitored from hour 0 to hour 5 after consumption of 0 gm of whey protein isolate
Arm Title
Protein consumption : 12.5 gm
Arm Type
Experimental
Arm Description
Participant's glucose levels are monitored from hour 0 to hour 5 after consumption of 12.5 gm of whey protein isolate
Arm Title
Protein consumption : 25 gm
Arm Type
Experimental
Arm Description
Participant's glucose levels are monitored from hour 0 to hour 5 after consumption of 25 gm of whey protein isolate
Arm Title
Protein consumption :37.5 gm
Arm Type
Experimental
Arm Description
Participant's glucose levels are monitored from hour 0 to hour 5 after consumption of 37.5 gm of whey protein isolate
Arm Title
Protein consumption : 50 gm
Arm Type
Experimental
Arm Description
Participant's glucose levels are monitored from hour 0 to hour 5 after consumption of 50 gm of whey protein isolate
Arm Title
Protein consumption : 62.5 gm
Arm Type
Experimental
Arm Description
Participant's glucose levels are monitored from hour 0 to hour 5 after consumption of 62.5 gm of whey protein isolate
Intervention Type
Dietary Supplement
Intervention Name(s)
Whey protein isolate
Intervention Description
Commercially available, FDA approved whey protein isolate for dietary supplementation
Primary Outcome Measure Information:
Title
Number of positive events for each protein amount.
Description
Events of postprandial hyperglycemia were defined as rise in glucose >50 mg/dL compared to baseline
Time Frame
from hour 0 to hour 5 after intervention

10. Eligibility

Sex
All
Minimum Age & Unit of Time
5 Years
Maximum Age & Unit of Time
17 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: . Duration of type 1 diabetes for > 1year. On insulin pump or multiple daily injection regimen Uses a personal Dexcom CGM Age: 5- 17 years HbA1C range: < 9% Exclusion Criteria: Hyperlipidemia Diabetic gastroparesis Dietary restrictions Celiac disease and other malabsorption syndromes Uncontrolled hypothyroidism Chronic use of steroids or antipsychotics Metabolic disorders of gluconeogenesis Use of oral hypoglycemic agents Participating in another clinical trial
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Dalia Dalle, MD
Organizational Affiliation
University Hospitals Cleveland Medical Center
Official's Role
Principal Investigator
Facility Information:
Facility Name
University Hospitals Cleveland medical Center
City
Cleveland
State/Province
Ohio
ZIP/Postal Code
44106
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Effect of Protein Intake on Post Prandial Hyperglycemia in Children and Adolescents With Type1 Diabetes Mellitus

We'll reach out to this number within 24 hrs